<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089423</url>
  </required_header>
  <id_info>
    <org_study_id>7430-2/1</org_study_id>
    <nct_id>NCT04089423</nct_id>
  </id_info>
  <brief_title>FujiLAM Prospective Evaluation Trial</brief_title>
  <official_title>Prospective Multicentre Evaluation of the Accuracy and Diagnostic Yield of the Fujifilm SILVAMP TB LAM (FujiLAM) Test for the Diagnosis of Tuberculosis in People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Diseases Institute, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ifakara Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Viet-Tiep Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Tuberculosis Control Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujifilm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omega Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tuberculosis and Lung Disease Hospital in Hai Phong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentre cohort study in which the accuracy and the diagnostic
      yield of the FujiLAM test will be assessed using a microbiological reference standard, an
      extended microbiological reference standard and a composite reference standard among
      inpatient and outpatient people living with HIV (PLHIV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined eMRS.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined CRS.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic yield, with 95% confidence interval, of FujiLAM test among eMRS positive patients and AlereLAM, Smear and Ultra (sputum, urine) as comparators (on Day 1 specimens).</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Diagnosis of Tuberculosis in People Living With HIV</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fujifilm SILVAMP TB LAM</intervention_name>
    <description>Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.</description>
    <other_name>Omega VISITECT® CD4 Advanced Disease test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult people living with HIV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult PLHIV (≥18 years), irrespective of their CD4 count and antiretroviral therapy
             (ART) status, at risk of having pulmonary and/or extra-pulmonary TB

          -  Inpatients: irrespective of TB symptoms

          -  Outpatients: at least one of the symptoms suggestive of TB (as defined by WHO*)

          -  written informed consent

          -  willingness to have a trial follow-up visit at 2-3 and 6 months after enrolment (e.g.
             not planning to relocate)

        Exclusion Criteria:

          -  Current anti-TB treatment *

          -  Any anti-TB treatment within 60 days prior to enrolment

          -  Any isoniazid preventive therapy within 6 months prior to enrolment * Patients
             starting anti-TB treatment at the time of enrolment will not be excluded from the
             trial provided that all trial specimens are collected before starting the 3rd dose of
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Ruhwald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FIND Head of TB programme</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rita Szekely, PhD</last_name>
    <phone>+41-22-749-2932</phone>
    <email>rita.szekely@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Nabeta, MD</last_name>
    <phone>+41-22-710-0590</phone>
    <email>pamela.nabeta@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malawi-Liverpool-Wellcome Trust Clinical Research Programme</name>
      <address>
        <city>Blantyre</city>
        <zip>Box 30096</zip>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter MacPherson, MD</last_name>
      <phone>+265 99 717 6230</phone>
      <email>peter.macpherson@lstmed.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIDRI-Africa University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graeme Meintjes, Prof</last_name>
      <phone>+27214066797</phone>
      <email>graemein@mweb.co.za</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Sossen, MD</last_name>
      <phone>+27763088376</phone>
      <email>blsossen@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis, PLHIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

